Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Dermatologic 3Plasma cell 2Myeloid 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Head & Neck 1Breast 1

Conditions

Neoplasm Metastasis 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Amplified Fragment Length Polymorphism Analysis × Tumor-Agnostic × Clear all
NCT01015560 2018-08-09

S0916, MLN1202 in Treating Patients With Bone Metastases

SWOG Cancer Research Network

Phase 2 Completed
44 enrolled 7 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡